Cell 1
Close

Do you have any questions?

Don't hesitate to contact us. We are happy to answer your questions.

Miltenyi Biomedicine
Friedrich-Ebert-Strasse 68
51429 Bergisch Gladbach
Germany
Get directions

Miltenyi Biomedicine Inc.
1201 Clopper Road,
Gaithersburg, MD 20878,
USA.
Get directions

Personalized cellular immunotherapies for serious diseases

Miltenyi Biomedicine is dedicated to developing innovative cancer and regenerative treatments for patients suffering from serious diseases with unmet medical needs

Cancer
Cancer Separate
Cart 1
Cancer 2
Cart Gradient

Personalized cellular immunotherapies for serious diseases

Miltenyi Biomedicine is dedicated to developing innovative cancer and regenerative treatments for patients suffering from serious diseases with unmet medical needs

Cell blue 1

Researching immunotherapies in hemato-oncology

At Miltenyi Biomedicine, we believe in the power that personalized cell and gene therapies have to make a difference for patients who have limited treatment options available today. Developments like Chimeric Antigen Receptor T (CAR T) cells are certainly ground-breaking innovations in treating cancer – and we strongly believe that, promising developments notwithstanding, there is significant room to improve available therapies. Our clinical research program includes: CAR T, CAR NK, our proprietary Adapter CAR™ and induced pluripotent stem cells (iPSC) technologies.

Our goal is to create more powerful and effective treatment options, with a sustainable and guaranteed supply, to treat patients worldwide in a timely manner.
Outstanding examples of Miltenyi’ s expertise in the therapeutic arena are: Immunotherapy through innovative CAR T cell approaches currently under study in international trials for solid tumors and hematological malignancies (for more information please refer to our
Pipeline below).

Cell Colored 1

We are currently developing a CAR T therapy to treat adult patients with relapsed or refractory diffuse large B cell lymphoma (DLBCL) after at least one line of treatment. Our zamtocabtagene autoleucel uniquely targets the combination of both CD19 and CD20 proteins on B cells. This promising investigational therapy candidate has been selected for the PRIority MEdicines scheme (PRIME) in the European Union. In addition, we have submitted an Investigational New Drug (IND) application for a new CAR T cell therapy to the Food and Drug Administration (FDA) in the United States. Further clinical development of this therapy candidate is planned for Asia Pacific.

Show more

If you would like to learn more about our research please contact us!

We believe that novel cell and gene therapies will change medicine forever.

We believe that novel cell and gene therapies will change medicine forever.

Antibody White A 1
Antibody White A 2

Our Research Platforms

CAR T Cells

What: Disease-specific autologous immune cells, created from the patient’s blood, that attack and destroy cancer cells. The retargeting of immune cells can be achieved by inserting new genetic information into the patient’s T cells via gene engineering.

Our Concept: Second-generation CAR T therapy optimized to overcome the limitations of current options. In particular, our dual and triple targeting is aimed at reducing disease escape mechanisms, thus providing new treatment options to patients who have not been helped by conventional therapies.

Method: T cells are collected from the patient and genetically engineered with a CAR construct. Our proprietary technology ensures optimized CAR T cell expansion in a timely manner.

Lead Candidates/Indications: We are developing several products for single, double and triple targeting. Our first disease target is DLBCL. Please check our pipeline for more information about other indications we are actively researching.

Show more
Antibody White A 3

Adapter CAR™

What: Adapter CAR cells are an improvement of the conventional CAR T technology. They are designed to allow targeting of multiple cancer antigens and control of their activity, thus increasing the safety and efficacy of CAR cells.

Our Concept: Instead of directly targeting a disease-associated antigen on a cancer cell, the CAR technology is split into two components – the CAR T cell and the adapter. The adapter CAR will only be active when both components are available.

Method: The adapter CAR cells are engineered not to recognize a target cell but rather a docking structure present in the adapter. The adapter itself consists of the docking structure and a cancer-specific binding domain. When the adapter is bound to a cancer cell, the CAR will bind to the adapter and initiate killing the cancer cell. The use of different adapters enables targeting different types of cancer cells with only one CAR, simplifying the treatment process and expanding treatment options. Moreover, this technology allows the activity of the CAR to be controlled by applying the adapter at different dose levels. The option to switch off the CAR’s activity is not addressed by current treatments, but it is believed to be important for solid tumors.

Lead Candidates/Indications: We are currently running a proof of concept study as part of our clinical research program in Relapse/Refractory NHL; and we are actively working on Relapse/Refractory AML.

Show more
Antibody White A 4

CAR NK Cells

What: Natural Killer (NK) cells belong to the innate immune system. They can be derived from healthy donors and genetically engineered, similarly to CAR T cells, to recognize a specific disease target.

Our Concept: CAR NK cells can be produced from a healthy donor. Compared to currently available CAR T cells, which are produced from the patient’s own T cells, this technology allows ‘off the shelf’ CAR cells to be manufactured, thus providing a convenient and rapid treatment option. Although the technology for delivering the genetic information into the NK cell is very similar to the technology used to engineer T cells, the NK cell has different characteristics compared to T cells. NK cells have an intrinsic anti-tumor activity without needing to be activated. Together with the anti-tumor activity delivered by the CAR, this synergy may enhance the anti-tumor activity of CAR NK cells and prevent antigen escape – thus providing a very efficient therapeutic option. In addition, the short persistence of CAR NK cells could offer a safer means of therapy in various diseases.

Method: Contrary to autologous immune cells, which are created from the patient’s own blood, allogenic CAR NK cells are generated from a healthy donor. The NK cells collected are genetically modified to express a specific CAR aimed at the target of interest.

Lead Candidates/Indications: The main indications for the future CAR NK cell product are hematologic malignancies in general, with special attention to developing a cell therapy candidate for AML.

Show more
Antibody White A 3

iPS Cells

What: Induced pluripotent stem (iPS) cells raise the possibility of producing custom-tailored cells for studying and treating numerous diseases and for use in regenerative medicine approaches.

Our Concept: Somatic cells from a donor or a patient are collected and genetically reprogrammed to become iPS cells, enabling products for regenerative approaches to be developed. iPS cells can differentiate into target cells (such as oligodendrocytes) and, subsequently, may regenerate normal tissue functions. We are optimizing a fully closed system to generate iPS cells to be used as a pristine source of differentiated cells.

Method: Once iPS cells are created, they can be expanded, stored and, if needed, expanded over and over again. They can then be differentiated into a spectrum of different cell types (to replace tissues affected by diseases, for example). This technology opens up new possibilities for personalized and/or off-the-shelf therapeutic products that would benefit a greater number of patients who currently have unmet therapeutic needs.

Lead Candidates/Indications: Our clinical research program is currently focusing on Parkinson’s disease, with several approaches under development.

Show more

Our pipeline

Miltenyi has a diverse portfolio of proprietary product candidates for hematologic cancers, with several clinical trials currently underway or planned for the near future. The graphic shows examples of product candidates in late pre-clinical and clinical development stages. Additionally we are actively expanding our pipeline by applying our platforms to degenerative disorders, and solid tumors such as pancreatic cancer, ovarian cancer and glioblastoma.

Technology
Indication
Preclinical
Phase 1
Phase 2

Zamtocabtagene autoleucel1

NCT03870945

Target:CD19CD20

Technology

Tandem CART
Indication
Preclinical
Phase 1
Phase 2
DLBCL
DLBCL
MCL
MCL
FL
FL
CLL
CLL

MB-CART 2219.1

Target:CD19CD22

Technology

Tandem CART
Indication
Preclinical
Phase 1
Phase 2
ALL
ALL

MB-CART 19.1

NCT03853616

Target:CD19

Technology

Mono CART
Indication
Preclinical
Phase 1
Phase 2
NHL
NHL
ALL
ALL

MB-CART 20.1

NCT03664635

Target:CD20

Technology

Mono CART
Indication
Preclinical
Phase 1
Phase 2
NHL
NHL

MB-CART 20.1

NCT03893019

Target:CD20

Technology

Mono CART
Indication
Preclinical
Phase 1
Phase 2
Melanoma
Melanoma

huBCMA

Target:BCMA

Technology

Mono CART
Indication
Preclinical
Phase 1
Phase 2
Myeloma
Myeloma

MB-dNPM1-TCR.1

Target:dNPM1

Technology

TCR
Indication
Preclinical
Phase 1
Phase 2
AML
AML

1 Zamtocabtagene autoleucel is a proposed International Nonproprietary Name (INN).

Our Chimeric Antigen Receptor T (CAR T) cell technology

Chimeric Antigen Receptor T (CAR T) cell technology has already shown significant success in fighting hematological cancers. These genetically engineered T cells – produced from the patient’s own immune cells – have demonstrated their potential to treat hematologic cancers in several clinical trials and approved indications.

However compared to other therapies, the prolonged manufacturing time can mean longer waiting time until patients can be treated. Therefore, we have developed a fast, robust manufacturing process to treat patients sooner and expand the number of patients that can be treated with these life-changing products. Furthermore, our innovative CAR T design simultaneously targets CD19 and CD20 proteins on B cells. It is hypothesized that such a dual-targeting approach can potentially reduce the risk of patient relapse. These innovations are aimed at providing patients with improved treatment options.

Show more
How does CAR T cell therapy work?
In order to manufacture CAR T cells, autologous T cells from the patient are collected and reprogrammed with genetic information (the CAR-genetic sequence) to recognize antigens on cancer cells. After inserting this new information, the CAR T cells are expanded. Once the target cell dose is reached, they are infused into the patient’s body, where the CAR T cells kill the patient's cancer cells and other cells carrying the specific antigen.

There is evidence that CAR T cells have the potential to persist in the patient, thus making them a personalized, living drug. Miltenyi has already developed several type of CAR T cells to optimize their efficacy in treating patients. For example a common tumor escape mechanism employed by cancer cells is to stop expressing the specific antigen recognized by the CAR T cells and thus become unrecognizable to the patient’s immune system. In this case, CAR T cells can be prepared to recognize two different antigens – which is called ‘dual targeting’ – which may help overcome tumor escape mechanisms. Both persistence and dual targeting have the potential to provide a durable response against cancer in patients who have failed one or more lines of therapy.
How are CAR T cells manufactured?
Our optimized method for CAR T cell manufacturing consists of 4 main steps. In the first step the patient’s T cells are enriched thus removing unwanted cell types to increase the efficiency of the manufacturing process and optimize the CAR T product. In the second step the enriched T cells are activated. That is a critical requirement to introduce the new genetic information (the CAR-genetic sequence). In the third step, a lentivirus containing the CAR-genetic sequence is used to transduce the activated T cells. Lentiviral vectors have been demonstrated to be safe in genetic engineering of T cells in several clinical trials. The fourth step expand the number of CAR T cells over several days to achieve the dose required for patient's treatment.
Cell Colored 2
Factory

The course of CAR T therapy

The full process – from leukapheresis to transfusion of the final product – takes approximately 2 weeks.

  • Icon 1

    The patient undergoes leukapheresis to collect the necessary number of T cells from the patient's blood.

  • Icon 2
    Icon 3

    Genetic engineering and expansion of CAR T cells. After fulfilling the release criteria, the CAR T cells are shipped back to the hospital. In the meantime, the patient undergoes preparative lymphodepletion chemotherapy at the treating institution to reduce the level of leukocytes in the blood.

  • Icon 4

    After lymphodepletion, the patient receives a transfusion containing the CAR T cells.

  • Icon 5

    The newly inserted CAR allows the CAR T cells to target the patient’s cancer cells.

Do you have any questions?

Do you have any questions?